Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12620996.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate cancer is known for its difficulties in preoperative staging of pelvic lymph nodes by conventional imaging techniques. Thus, a histopathologic examination of the pelvic lymphadenectomy specimen is mandatory for patients at risk for metastatic disease. The aim of this study was to evaluate the strength and accuracy of (11)C-choline PET in preoperative noninvasive staging of pelvic lymph nodes in prostate cancer. In a prospective study we examined 67 consecutive patients with histologically proven prostate cancer with (11)C-choline PET. The results of PET were compared with the results of histology of the pelvic lymph nodes and with the follow-up data. Conventional axial imaging was routinely performed using MRI or CT. The sensitivity, specificity, and accuracy of (11)C-choline PET were calculated. Fifteen patients had histologically proven lymph node metastases. (11)C-Choline PET was true-positive in 12 of 15 patients and false-negative in 3 patients. Fifty-two patients had no lymph node metastases. (11)C-Choline PET was true-negative in 50 of 52 patients and false-positive in 2 patients. We calculated a sensitivity of (11)C-choline PET for staging metastatic lymph node disease of 80%, a specificity of 96%, and an accuracy of 93%. Next, (11)C-choline PET detected solitary extraregional lymph node metastases in 5 of 12 patients with nodal metastases. This study showed that (11)C-choline PET is sensitive and accurate in preoperative staging of pelvic lymph nodes in prostate cancer.
Medical subject headings
- Adenocarcinoma
- Carbon Radioisotopes
- Choline
- Lymph Nodes
- Prostatic Neoplasms
- Radiopharmaceuticals
- Tomography, Emission-Computed